<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40300639</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Natural History of Anal Strictures in Pediatric-Onset Crohn's Disease: Long-term Follow-up of a Population-Based Study.</ArticleTitle><Pagination><StartPage>984</StartPage><EndPage>991</EndPage><MedlinePgn>984-991</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003788</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The risk and clinical course of anal stricture observed in Crohn's disease remains poorly known, particularly in pediatric-onset Crohn's disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the long-term clinical course of anal stricture in pediatric-onset Crohn's disease using data from a population-based cohort.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A retrospective observational study from a prospective population-based registry.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Population-based study in Northern France.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">All patients with a diagnosis of Crohn's disease before the age of 17 years between 1988 and 2011 within the population-based registry EPIMAD were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Primary outcome was the cumulative risk of anal stricture. Secondary outcomes included include risk of anal cancer, surgery, stoma, and risk factors associated with anal stricture.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1007 patients were included (median age at diagnosis 14.5 years [interquartile range, 12.0-16.1]; median duration of follow-up 8.8 years [interquartile range, 4.6-14.2]). Among them, 1 patient (0.1%) had an anal stricture at diagnosis and 26 (2.6%) had an anal stricture during follow-up. From diagnosis, the 5- and 10-year cumulative incidence of anal stricture at was 0.6% (95% CI, 0.1-1.1) and 1.4% (95% CI, 0.5-2.3), respectively. Twenty-five patients (n = 25/27; 93%) had at least 1 episode of anal ulceration or fistulizing perineal Crohn's disease. In multivariable analysis, extraintestinal manifestations (HR 2.2; 95% CI, 1.0-4.8; p = 0.0270), colonic location (colonic vs ileocolonic HR 1.2; 95% CI, 0.6-2.7; p = 0.0064) and a history of fistulizing perineal Crohn's disease (HR 9.9; 95% CI, 4.3-22.8; p &lt; 0.0001) were significantly associated with anal stricture. After a median follow-up of 6.2 years (2.4-10.6), 11 patients (41%) required at least 1 anal dilation, and healing was observed in 1 patient. One patient (3.7%) had an anal cancer 7 years after stricture diagnosis and 9 patients (33%) needed a stoma. Anal stricture was significantly associated with the need for stoma (HR 5.8; 95% CI, 2.3-14.3; p = 0.0002).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The retrospective design makes the study prone to selection bias and residual confounding.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Within a population-based cohort of pediatric-onset Crohn's diease, the 10-year cumulative incidence of anal stricture was 1.4%, with associations identified with colonic disease location and fistulizing perianal involvement. The presence of an anal stricture was linked to a 5-fold increase in the likelihood of stoma formation. See Video Abstract .</AbstractText><AbstractText Label="HISTORIA NATURAL DE LAS ESTENOSIS ANALES EN LA ENFERMEDAD DE CROHN DE INICIO PEDITRICO SEGUIMIENTO A LARGO PLAZO DE UN ESTUDIO POBLACIONAL" NlmCategory="UNASSIGNED">ANTECEDENTES:El riesgo y la evoluci&#xf3;n cl&#xed;nica de la estenosis anal observada en la enfermedad de Crohn siguen siendo poco conocidos, especialmente en la enfermedad de Crohn de inicio pedi&#xe1;trico.OBJETIVO:Investigar la evoluci&#xf3;n cl&#xed;nica a largo plazo de la estenosis anal en la EC de inicio pedi&#xe1;trico utilizando datos de una cohorte poblacional.DISE&#xd1;O:Estudio observacional retrospectivo a partir de un estudio poblacional prospectivo.ENTORNO CLINICO:Estudio poblacional en el norte de Francia.PACIENTES:Todos los pacientes con diagn&#xf3;stico de enfermedad de Crohn antes de los 17 a&#xf1;os, entre 1988 y 2011, incluidos en el registro poblacional EPIMAD.PRINCIPALES MEDIDAS DE RESULTADOS:La variable principal fue el riesgo acumulado de estenosis anal. Las variables secundarias incluyeron el riesgo de c&#xe1;ncer anal, cirug&#xed;a, estoma y factores de riesgo asociados con la estenosis anal.RESULTADOS:Se incluyeron 1007 pacientes (mediana de edad al diagn&#xf3;stico: 14,5 a&#xf1;os; RIQ: 12,0-16,1), con una mediana de seguimiento de 8,8 a&#xf1;os (RIQ: 4,6-14,2). Un paciente (0,1%) present&#xf3; estenosis anal al diagn&#xf3;stico y 26 (2,6%) durante el seguimiento. Desde el diagn&#xf3;stico, la incidencia acumulada de estenosis anal a los 5 y 10 a&#xf1;os fue del 0,6% (IC del 95%: 0,1-1,1) y del 1,4% (IC del 95%: 0,5-2,3), respectivamente. Veinticinco pacientes (n = 25/27, 93%) presentaron al menos un episodio de ulceraci&#xf3;n anal o enfermedad de Crohn perineal fistulizante. En el an&#xe1;lisis multivariable, las manifestaciones extraintestinales (HR 2,2, IC del 95 %, 1,0-4,8, p = 0,0270), la localizaci&#xf3;n col&#xf3;nica (L2 vs. L3 HR 1,2, IC del 95 %, 0,6-2,7, p = 0,0064) y el antecedente de enfermedad de Crohn perineal fistulizante (HR 9,9, IC del 95 %, 4,3-22,8, p &lt; 0,0001) se asociaron significativamente con la estenosis anal. Tras una mediana de seguimiento de 6,2 a&#xf1;os (2,4-10,6), 11 (41 %) pacientes requirieron al menos una dilataci&#xf3;n anal, y se observ&#xf3; curaci&#xf3;n en un paciente. Un paciente (3,7 %) present&#xf3; c&#xe1;ncer anal 7 a&#xf1;os despu&#xe9;s del diagn&#xf3;stico de la estenosis, y 9 (33 %) pacientes necesitaron un estoma. La estenosis anal se asoci&#xf3; significativamente con la necesidad de estoma (HR 5,8; IC del 95 %: 2,3-14,3; p = 0,0002).LIMITACIONES:El dise&#xf1;o retrospectivo del estudio lo hace propenso a sesgos de selecci&#xf3;n y factores de confusi&#xf3;n residuales.CONCLUSI&#xd3;N:En una cohorte poblacional de pacientes con enfermedad de Crohn de inicio pedi&#xe1;trico, la incidencia acumulada de estenosis anal a 10 a&#xf1;os fue del 1,4 %, con asociaciones identificadas con la localizaci&#xf3;n de la enfermedad col&#xf3;nica y la afectaci&#xf3;n perianal fistulizante. La presencia de estenosis anal est&#xe1; ligada a quintuplicar la probabilidad de formaci&#xf3;n de estoma. (Traducci&#xf3;n- Dr. Francisco M. Abarca-Rendon).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mortreux</LastName><ForeName>Perrine</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leroyer</LastName><ForeName>Ariane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Economic Health, Lille University Hospital, EPIMAD Registry, Regional House of Clinical Research, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ley</LastName><ForeName>Delphine</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupont-Lucas</LastName><ForeName>Claire E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Pediatric Gastroenterology, Caen University Hospital, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Le Havre Hospital, Le Havre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillon</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Economic Health, Lille University Hospital, EPIMAD Registry, Regional House of Clinical Research, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wils</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coevoet</LastName><ForeName>Hugues B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, H&#xf4;pital Priv&#xe9; Les Bonnettes, Arras, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paupard</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Dunkerque Hospital, Dunkerque, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gower-Rousseau</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Reims University Hospital, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siproudhis</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Rennes University Hospital, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Universit&#xe9; de Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis," CHU Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turck</LastName><ForeName>Dominique D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savoye</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Universit&#xe9; de Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis," CHU Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarter</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Economic Health, Lille University Hospital, EPIMAD Registry, Regional House of Clinical Research, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fumery</LastName><ForeName>Mathurin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2337-2902</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>EPIMAD Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C536215">Pediatric Crohn's disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003251" MajorTopicYN="N">Constriction, Pathologic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001004" MajorTopicYN="Y">Anus Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001003" MajorTopicYN="N">Anal Canal</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001005" MajorTopicYN="N">Anus Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anal stricture</Keyword><Keyword MajorTopicYN="N">Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Perianal Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Population-based</Keyword><Keyword MajorTopicYN="N">Stoma</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Al Hameedi</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al Khatib</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al Turk</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agoute</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andre</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonietti</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aouakli</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armand</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armengol-Debeir</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aroichane</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assi</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aubet</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auxenfants</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avram</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ayafi-Ramelot</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Azzouzi</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bankovski</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbry</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bardoux</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baron</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baudet</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bayart</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bazin</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bebahani</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becqwort</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bellati</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benet</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benali</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benard</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benguigui</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ben Soussan</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bental</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berkelmans</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernet</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernou</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernou-Dron</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertot</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertiaux-Vanda&#xeb;le</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertrand</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Billoud</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biron</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bismuth</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bleuet</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blondel</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blondin</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bobula</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bohon</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bondjemah</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boniface</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonkovski</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonni&#xe8;re</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonvarlet</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonvarlet</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boruchowicz</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bostvironnois</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boualit</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouazza</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouche</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boudaillez</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourgeaux</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourgeois</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourguet</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourienne</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boutaleb</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouthors</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Branche</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bray</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brazier</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Breban</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bridenne</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brihier</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bril</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brung-Lefebvre</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bulois</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burgiere</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Butel</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canva</LastName><ForeName>J Y</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canva-Delcambre</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capron</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cardot</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carette</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carpentier</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cartier</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cassar</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cassagnou</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castex</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Catala</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cattan</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Catteau</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caujolle</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cayron</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chandelier</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chantre</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charles</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charneau</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chavance-Thelu</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheny</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chirita</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choteau</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Claerbout</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clergue</LastName><ForeName>P Y</ForeName><Initials>PY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coevoet</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collet</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colombel</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coopman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cordiez</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corvisart</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cortot</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couttenier</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crinquette</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crombe</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dadamessi</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daoudi</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dapvril</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davion</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dautreme</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Debas</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Decoster</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Degrave</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dehont</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delatre</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delcenserie</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delesalle</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delette</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delgrange</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delhoustal</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delmotte</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Demmane</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deregnaucourt</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Descombes</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desechalliers</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desmet</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desreumaux</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desseaux</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desurmont</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devienne</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devouge</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devred</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devroux</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dewailly</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dharancy</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Fiore</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Djedir</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Djedir</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doleh</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dreher-Duwat</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dubois</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duburque</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducatillon</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duclay</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducrocq</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducrot</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducrotte</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dufilho</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duhamel</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dujardin</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dumant-Forest</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dupas</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dupont</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duranton</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duriez</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duveau</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>El Achkar</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>El Farisi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elie</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elie-Legrand</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elkhaki</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eoche</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Essmaeel</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evrard</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evrard</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fatome</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Filoche</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finet</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flahaut</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flamme</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foissey</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fournier</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foutrein-Comes</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foutrein</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fremond</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frere</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fumery</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallais</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamblin</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ganga</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerard</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geslin</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gheyssens</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghossini</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghrib</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilbert</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillet</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godart</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godard</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godchaux</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godchaux</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goegebeur</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goria</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gottrand</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gower</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grandmaison</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Groux</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guedon</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerbeau</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gueroult-Dero</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guillard</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guillem</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guillemot</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guimber</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haddouche</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hakim</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanon</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hautefeuille</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heckestweiller</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hecquet</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hedde</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hellal</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henneresse</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heyman</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heraud</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herve</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hochain</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Houssin-Bailly</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Houcke</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huguenin</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iobagiu</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Istanboli</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ivanovic</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iwanicki-Caron</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Janicki</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jarry</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joly</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jonas</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jouvenet</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katherin</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerleveo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khachfe</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiriakos</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiriakos</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohut</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornhauser</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koutsomanis</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laberenne</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacotte</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laffineur</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lagarde</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lalanne</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lalieu</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lannoy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lapchin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laprand</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laude</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leblanc</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lecieux</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lecleire</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leclerc</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Couteulx</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ledent</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lefebvre</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lefiliatre</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Goffic</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Legrand</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Grix</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lelong</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leluyer</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lemaitre</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lenaerts</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lepeut</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lepileur</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leplat</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lepoutre-Dujardin</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leroi</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leroy</LastName><ForeName>M Y</ForeName><Initials>MY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Roy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>X</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lescanne-Darchis</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lescut</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lescut</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leurent</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ley</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lhermie</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Libier</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lion</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lisambert</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loge</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loire</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loreau</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Louf</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Louvet</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lubret</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luciani</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lucidarme</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lugand</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macaigne</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maetz</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maillard</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mancheron</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manolache</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marks-Brunel</LastName><ForeName>A B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marre</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marti</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marzloff</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathurin</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mauillon</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maunoury</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maupas</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Medam Djomo</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mechior</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melki</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesnard</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Metayer</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Methari</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meurisse</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meurisse</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michaud</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mirmaran</LastName><ForeName>X</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Modaine</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monthe</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morel</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mortier</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moulin</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mouterde</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mozziconaci</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudry</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nachury</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ngo</LastName><ForeName>M D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>N'Guyen Khac</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Notteghem</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ollevier</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ostyn</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouraghi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oussadou</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouvry</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paillot</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Painchart</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panien-Claudot</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paoletti</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papazian</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parent</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pariente</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paris</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patrier</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paupard</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pauwels</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pauwels</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Penninck</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petit</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piat</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piotte</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plane</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plouvier</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pollet</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pommelet</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pop</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pordes</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pouchain</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prades</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prevost</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prevost</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quartier</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quesnel</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Queuniet</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinton</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabache</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabelle</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raclot</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ratajczyk</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rault</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Razemon</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reix</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renaut-Vantroys</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Revillion</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riachi</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richez</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riault</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roger</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roux</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rudelli</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saber</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Savoye</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlossberg</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sefrioui</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Segrestin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seguy</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seminur</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Serin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seryer</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sevenet</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shekh</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silvie</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simon</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spyckerelle</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Talbodec</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tavernier</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tchandeu</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Techy</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thelu</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thevenin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thiebault</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thorel</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thuillier</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tielman</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tode</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toisin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tonnel</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Touchais</LastName><ForeName>J Y</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toumelin</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Touze</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tranvouez</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Triplet</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Triki</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turck</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uhlen</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaillant</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valmage</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanco</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandaele-Bertiaux</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandamme</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderbecq</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vander Eecken</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandermolen</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandevenne</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandeville</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandewalle</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandewalle</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaneslander</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanhoove</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanrenterghem</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanveuren</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varlet</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vasies</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verbiese</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verlynde</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vernier-Massouille</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vermelle</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verne</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vezilier-Cocq</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vigneron</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vincendet</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Viot</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Voiment</LastName><ForeName>Y M</ForeName><Initials>YM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wacrenier</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waeghemaecker</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wallez</LastName><ForeName>J Y</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wantiez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wartel</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weber</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willocquet</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wizla</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolschies</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaharia</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaoui</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zalar</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaouri</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zellweger</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ziade</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>30</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>29</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40300639</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003788</ArticleId><ArticleId IdType="pii">00003453-202508000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn&#x2019;s disease. Inflamm Bowel Dis. 2002;8:244&#x2013;250.</Citation></Reference><Reference><Citation>Freeman HJ. Natural history and clinical behavior of Crohn&#x2019;s disease extending beyond two decades. J Clin Gastroenterol. 2003;37:216&#x2013;219.</Citation></Reference><Reference><Citation>Peyrin-Biroulet L, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Perianal Crohn&#x2019;s disease findings other than fistulas in a population-based cohort. Inflamm Bowel Dis. 2012;18:43&#x2013;48.</Citation></Reference><Reference><Citation>Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn&#x2019;s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875&#x2013;880.</Citation></Reference><Reference><Citation>Zhao M, Lo BZS, Vester-Andersen MK, Vind I, Bendtsen F, Burisch J. A 10-year follow-up study of the natural history of perianal Crohn&#x2019;s disease in a Danish population-based inception cohort. Inflamm Bowel Dis. 2019;25:1227&#x2013;1236.</Citation></Reference><Reference><Citation>Keljo DJ, Markowitz J, Langton C, et al. Course and treatment of perianal disease in children newly diagnosed with Crohn&#x2019;s disease. Inflamm Bowel Dis. 2009;15:383&#x2013;387.</Citation></Reference><Reference><Citation>Adler J, Dong S, Eder SJ, Dombkowski KJ; ImproveCareNow Pediatric IBD Learning Health System. Perianal Crohn disease in a large multicenter pediatric collaborative. J Pediatr Gastroenterol Nutr. 2017;64:e117&#x2013;e124.</Citation></Reference><Reference><Citation>Brochard C, Siproudhis L, Wallenhorst T, et al. Anorectal stricture in 102 patients with Crohn&#x2019;s disease: natural history in the era of biologics. Aliment Pharmacol Ther. 2014;40:796&#x2013;803.</Citation></Reference><Reference><Citation>Bouguen G, Siproudhis L, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Nonfistulizing perianal Crohn&#x2019;s disease: clinical features, epidemiology, and treatment. Inflamm Bowel Dis. 2010;16:1431&#x2013;1442.</Citation></Reference><Reference><Citation>Linares L, Moreira LF, Andrews H, Allan RN, Alexander-Williams J, Keighley MR. Natural history and treatment of anorectal strictures complicating Crohn&#x2019;s disease. Br J Surg. 1988;75:653&#x2013;655.</Citation></Reference><Reference><Citation>Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut. 1994;35:1433&#x2013;1438.</Citation></Reference><Reference><Citation>Ley D, Leroyer A, Dupont C, et al.; Epimad Group. New therapeutic strategies have changed the natural history of pediatric Crohn&#x2019;s disease: a two-decade population-based study. Clin Gastroenterol Hepatol. 2022;20:2588&#x2013;2597.e1.</Citation></Reference><Reference><Citation>Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314&#x2013;1321.</Citation></Reference><Reference><Citation>Fernandes MA, Verstraete SG, Garnett EA, Heyman MB. Addition of histology to the paris classification of pediatric Crohn disease alters classification of disease location. J Pediatr Gastroenterol Nutr. 2016;62:242&#x2013;245.</Citation></Reference><Reference><Citation>Mortreux P, Leroyer A, Ley D, et al. Natural history of anal stricture in pediatric-onset Crohn&#x2019;s disease: a two-decades population-based study. J Crohns Colitis. 2023;17:i315&#x2013;i316.</Citation></Reference><Reference><Citation>Wolff BG, Culp CE, Beart RW Jr, Ilstrup DM, Ready RL. Anorectal Crohn&#x2019;s disease. A long-term perspective. Dis Colon Rectum. 1985;28:709&#x2013;711.</Citation></Reference><Reference><Citation>Keighley MR, Allan RN. Current status and influence of operation on perianal Crohn&#x2019;s disease. Int J Colorectal Dis. 1986;1:104&#x2013;107.</Citation></Reference><Reference><Citation>Brochard C, Rabilloud ML, Hamonic S, et al.; Groupe ABERMAD. Natural history of perianal Crohn&#x2019;s disease: long-term follow-up of a population-based cohort. Clin Gastroenterol Hepatol. 2020;20:e102&#x2013;e110.</Citation></Reference><Reference><Citation>Fumery M, Pariente B, Sarter H, et al.; Epimad Group. Long-term outcome of pediatric-onset Crohn&#x2019;s disease: a population-based cohort study. Dig Liver Dis. 2019;51:496&#x2013;502.</Citation></Reference><Reference><Citation>Singh S, Ding NS, Mathis KL, et al. Systematic review with meta-analysis: faecal diversion for management of perianal Crohn&#x2019;s disease. Aliment Pharmacol Ther. 2015;42:783&#x2013;792.</Citation></Reference><Reference><Citation>Burke JP. Role of fecal diversion in complex Crohn&#x2019;s disease. Clin Colon Rectal Surg. 2019;32:273&#x2013;279.</Citation></Reference><Reference><Citation>Hughes LE. Clinical classification of perianal Crohn&#x2019;s disease. Dis Colon Rectum. 1992;35:928&#x2013;932.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40035463</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Approaches to Surgical Management of Anorectal Melanoma in the Pre- and Post-Immunotherapy Eras.</ArticleTitle><Pagination><StartPage>746</StartPage><EndPage>752</EndPage><MedlinePgn>746-752</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003690</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although revolutionary in cutaneous melanoma, immune checkpoint inhibitors have shown reduced efficacy in anorectal melanoma. Nevertheless, their emergence and the possibility of improved outcomes may have changed the surgical management paradigm.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review the surgical management of anorectal melanoma in pre- and postimmunotherapy eras.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A retrospective cohort study from the Melanoma Institute Australia Research Database.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">A quaternary melanoma referral center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with anorectal melanoma from 1958 to 2021 were included.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">The use of abdominoperineal resection and wide local excision were compared in pre- and postimmunotherapy eras from the first use in 2014.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Type of surgery performed over time and overall survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 56 patients were identified with anal (57.1%), anorectal (16.1%), and rectal melanoma (26.8%). Initial management was abdominoperineal resection (37.5%), low anterior resection (3.6%), wide local excision (46.4%), and nonsurgical (12.5%) in metastatic or unresectable disease. Immunotherapy and targeted therapies were used in 21 patients (37.5%) from 2014, with no difference in mode of surgical management in pre- and postimmunotherapy eras ( p = 0.134). Five-year survival was 12.5% for the entire cohort, with no significant difference comparing patients receiving wide local excision or abdominoperineal resection (15.4% vs 14.3%, log rank p = 0.77). Involved margins were significantly associated with wide local excision (15.4% vs 4.8%, p = 0.016) with similar rates of local recurrence (15.4% vs 14.3%, p = 0.58).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The rarity of anorectal melanoma resulted in a small cohort managed over 63 years. Early checkpoint inhibitor trials excluded patients with mucosal melanoma, limiting access in this cohort.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite the introduction of immunotherapy, surgery remains pivotal in the management of anorectal melanoma. Surgical resection may be curative and prevent morbidity due to locoregional progression, but it can come at the cost of reduced quality of life. Centralized management in experienced centers should be encouraged for optimal multidisciplinary management. See Video Abstract .</AbstractText><AbstractText Label="ENFOQUES EN EL EL TRATAMIENTO QUIRRGICO DEL MELANOMA ANORECTAL EN LAS EPOCAS PREVIA Y POSTERIOR A LA INMUNOTERAPIA" NlmCategory="UNASSIGNED">ANTECEDENTES:Si bien han sido revolucionarios en el tratamiento del melanoma cut&#xe1;neo, los inhibidores de los puntos de control inmunitario han demostrado reducida eficacia en el tratamiento del melanoma ano-rectal. Sin embargo, su advenimiento y la posibilidad de obtener mejores resultados podr&#xed;an haber cambiado el paradigma del tratamiento quir&#xfa;rgico.OBJETIVO:Revisar el tratamiento quir&#xfa;rgico del melanoma ano-rectal en las &#xe9;pocas previa y posterior a la inmunoterapia.DISE&#xd1;O:Estudio retrospectivo de cohortes de la base de datos de investigaci&#xf3;n del Instituto del Melanoma de Australia (MRD2).ESCENARIO:Centro de referencia cuaternaria para melanomas.PACIENTES:Pacientes con melanoma ano-rectal desde 1958 hasta 2021.INTERVENCIONES:Se compar&#xf3; la resecci&#xf3;n abdominoperineal y la excisi&#xf3;n local ampliada en las &#xe9;pocas previa y posterior a la inmunoterapia desde su primer uso en 2014.PRINCIPALES MEDIDAS DE RESULTADOS:Tipo de cirug&#xed;a realizada a lo largo del tiempo y sobrevida general.RESULTADOS:Se identificaron 56 pacientes con melanoma anal (57,1%), ano-rectal (16,1%) y rectal (26,8%). El tratamiento inicial fue la resecci&#xf3;n abdominoperineal (37,5%), la resecci&#xf3;n anterior baja (3,6%), la excisi&#xf3;n local amplia (46,4%) y el tratamento no quir&#xfa;rgico (12,5%) en enfermedad metast&#xe1;sica o irresecable. Se utilizaron inmunoterapia y terapias dirigidas en 21 pacientes (37,5%) a partir de 2014 sin diferencias en el modo de tratamiento quir&#xfa;rgico en las &#xe9;pocas previas y posteriores a la inmunoterapia ( p = 0,134). La supervivencia a 5 a&#xf1;os fue del 12,5% para toda la cohorte sin diferencias significativas al comparar a los pacientes que recibieron escisi&#xf3;n local amplia o resecci&#xf3;n abdominoperineal (15,4% frente a 14,3%, log rank p = 0,77). Los m&#xe1;rgenes afectados se asociaron significativamente con una escisi&#xf3;n local amplia (15,4% frente a 4,8% p = 0,016) con tasas similares de recurrencia local (15,4% frente a 14,3% p = 0,58).LIMITACIONES:El melanoma ano-rectal es poco frecuente, por lo que presentamos una peque&#xf1;a cohorte tratada a lo largo de ocho d&#xe9;cadas. Los primeros ensayos con inhibidores de puntos de control excluyeron a los pacientes con melanoma mucoso, lo que limit&#xf3; el acceso en esta cohorte.CONCLUSIONES:A pesar del advenimiento de la inmunoterapia, la cirug&#xed;a sigue siendo fundamental en el tratamiento del melanoma ano-rectal. La resecci&#xf3;n quir&#xfa;rgica puede ser curativa y prevenir la morbilidad debido a la progresi&#xf3;n locorregional, pero puede tener el costo de una calidad de vida reducida. Finalmente, debe promoverse el tratamiento centralizado en centros experimentados para un tratamiento multidisciplinario &#xf3;ptimo. (Traducci&#xf3;n-Dr. Xavier Delgadillo ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pasch</LastName><ForeName>James A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-5720-507</Identifier><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal North Shore Hospital NSW, St Leonards, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wendy S</ForeName><Initials>WS</Initials><Identifier Source="ORCID">0000-0003-0997-7742</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrine Surgery, St. George Hospital, Kogarah, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kabir</LastName><ForeName>Shahrir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal North Shore Hospital NSW, St Leonards, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pennington</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="Y">Melanoma</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001005" MajorTopicYN="Y">Anus Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="Y">Proctectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anorectal</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">Melanoma</Keyword><Keyword MajorTopicYN="N">Mucosal</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>4</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>4</Day><Hour>8</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40035463</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003690</ArticleId><ArticleId IdType="pii">00003453-202506000-00016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Meguerditchian AN, Meterissian SH, Dunn KB. Anorectal melanoma: diagnosis and treatment. Dis Colon Rectum. 2011;54:638&#x2013;644.</Citation></Reference><Reference><Citation>Adileh M, Yuval JB, Huang S, et al. Anorectal mucosal melanoma in the era of immune checkpoint inhibition: should we change our surgical management paradigm? Dis Colon Rectum. 2021;64:555&#x2013;562.</Citation></Reference><Reference><Citation>Dodds TJ, Wilmott JS, Jackett LA, et al. Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. Pathology. 2019;51:39&#x2013;45.</Citation></Reference><Reference><Citation>Fastner S, Hieken TJ, McWilliams RR, Hyngstrom J. Anorectal melanoma. J Surg Oncol. 2023;128:635&#x2013;644.</Citation></Reference><Reference><Citation>Yang HM, Hsiao SJ, Schaeffer DF, et al. Identification of recurrent mutational events in anorectal melanoma. Mod Pathol. 2017;30:286&#x2013;296.</Citation></Reference><Reference><Citation>Taylor JP, Stem M, Yu D, et al. Treatment strategies and survival trends for anorectal melanoma: is it time for a change? World J Surg. 2019;43:1809&#x2013;1819.</Citation></Reference><Reference><Citation>Brady MS, Kavolius JP, Quan SH. Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center. Dis Colon Rectum. 1995;38:146&#x2013;151.</Citation></Reference><Reference><Citation>Matsuda A, Miyashita M, Matsumoto S, et al. Abdominoperineal resection provides better local control but equivalent overall survival to local excision of anorectal malignant melanoma: a systematic review. Ann Surg. 2015;261:670&#x2013;677.</Citation></Reference><Reference><Citation>Iddings DM, Fleisig AJ, Chen SL, Faries MB, Morton DL. Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? Ann Surg Oncol. 2010;17:40&#x2013;44.</Citation></Reference><Reference><Citation>Bleicher J, Cohan JN, Huang LC, et al. Trends in the management of anorectal melanoma: a multi-institutional retrospective study and review of the world literature. World J Gastroenterol. 2021;27:267&#x2013;280.</Citation></Reference><Reference><Citation>Perez DR, Trakarnsanga A, Shia J, et al. Locoregional lymphadenectomy in the surgical management of anorectal melanoma. Ann Surg Oncol. 2013;20:2339&#x2013;2344.</Citation></Reference><Reference><Citation>Ciarrocchi A, Pietroletti R, Carlei F, Amicucci G. Extensive surgery and lymphadenectomy do not improve survival in primary melanoma of the anorectum: results from analysis of a large database (SEER). Colorectal Dis. 2017;19:158&#x2013;164.</Citation></Reference><Reference><Citation>von EE, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453&#x2013;1457.</Citation></Reference><Reference><Citation>Ballantyne AJ. Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. Am J Surg. 1970;120:425&#x2013;431.</Citation></Reference><Reference><Citation>Martin-Perez B, Andrade-Ribeiro GD, Hunter L, Atallah S. A systematic review of transanal minimally invasive surgery (TAMIS) from 2010 to 2013. Tech Coloproctol. 2014;18:775&#x2013;788.</Citation></Reference><Reference><Citation>Nilsson PJ, Ragnarsson-Olding BK. Importance of clear resection margins in anorectal malignant melanoma. Br J Surg. 2010;97:98&#x2013;103.</Citation></Reference><Reference><Citation>Cancer Council Australia. Melanoma. Clinical practice guidelines for the diagnosis and management of melanoma. https://www.cancer.org.au/clinical-guidelines/skin-cancer/melanoma . Accessed December 27, 2024.</Citation></Reference><Reference><Citation>Smith HG, Bagwan I, Board RE, et al. Ano-uro-genital mucosal melanoma UK national guidelines. Eur J Cancer. 2020;135:22&#x2013;30.</Citation></Reference><Reference><Citation>Falch C, Mueller S, Kirschniak A, Braun M, Koenigsrainer A, Klumpp B. Anorectal malignant melanoma: curative abdominoperineal resection: patient selection with 18F-FDG-PET/CT. World J Surg Oncol. 2016;14:185.</Citation></Reference><Reference><Citation>Ogata D, Tsutsui K, Namikawa K, et al. Treatment outcomes and prognostic factors in 47 patients with primary anorectal malignant melanoma in the immune therapy era. J Cancer Res Clin Oncol. 2023;149:749&#x2013;755.</Citation></Reference><Reference><Citation>Dimitriou F, Namikawa K, Reijers ILM, et al. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Ann Oncol. 2022;33:968&#x2013;980.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39508482</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Rectal Cancer Watch-and-Wait Management: Experience of 545 Patients From the US Rectal Cancer Research Group.</ArticleTitle><Pagination><StartPage>180</StartPage><EndPage>189</EndPage><MedlinePgn>180-189</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003586</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The use of a watch-and-wait management strategy after a complete clinical response to neoadjuvant therapy for rectal cancer is increasing. However, insights into implementation, treatments, and outcomes on a national level in the United States are limited.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate and report on watch-and-wait management practices and outcomes in the United States.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Multicenter.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with stage II or III rectal cancer who underwent intentional watch-and-wait management between January 2015 and August 2022.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Patient and tumor characteristics, neoadjuvant treatment and response, local cancer regrowth and metastasis, salvage surgery, overall survival, and disease-specific survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 545 patients from 33 centers, follow-up was 21 months (range, 9-37). Total neoadjuvant therapy or other types of neoadjuvant therapy were used in 395 (72%) and 150 (28%) patients, respectively. The estimated 3-year local regrowth rate was 23.8% (95% CI, 19.1%-29.4%). Patients with local regrowth had higher distant metastases incidence (14.2% vs 3.5%, p &lt; 0.001). Salvage surgery was performed in 74 of 84 patients (88%) with local regrowth and included rectal resection in 66 patients (89%) and local excision in 8 (11%). Of 64 salvage resections with known pathology results, 58 (91%) were margin-negative. Overall, 3-year overall survival was 94.8% (95% CI, 90.5%-97.2%) and 3-year disease-specific survival was 96.2% (95% CI, 91.8%-98.2%). Patients with and without local regrowth exhibited 3-year overall survival of 83.6% (95% CI, 68.4%-91.9%) and 97.7% (95% CI, 93.3%-99.2%), respectively.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective study.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This multicenter study indicates that the watch-and-wait approach for locally advanced rectal cancer is feasible with acceptable outcomes across a variety of geographical regions and practice settings in the United States. Local regrowth and distant metastasis rates were within published norms and salvage surgery proved effective. See Video Abstract .</AbstractText><AbstractText Label="MANEJO DE ESPERA Y OBSERVACIN DEL CNCER RECTAL EXPERIENCIA DE PACIENTES DEL GRUPO DE INVESTIGACIN DEL CNCER RECTAL DE EE UU" NlmCategory="UNASSIGNED">ANTECEDENTES:El uso de una estrategia de manejo de observaci&#xf3;n y espera despu&#xe9;s de una respuesta cl&#xed;nica completa a la terapia neoadyuvante para el c&#xe1;ncer de recto est&#xe1; aumentando. Sin embargo, los conocimientos sobre la implementaci&#xf3;n, los tratamientos y los resultados, a nivel nacional de los Estados Unidos, son limitados.OBJETIVO:Investigar e informar sobre las pr&#xe1;cticas y los resultados del manejo de observaci&#xf3;n y espera en los EE. UU.DISE&#xd1;O:Estudio retrospectivo.ESCENARIO:Multic&#xe9;ntrico.PACIENTES:Pacientes con c&#xe1;ncer de recto en estadio II o III que se sometieron a un manejo de observaci&#xf3;n y espera intencional entre enero de 2015 y agosto de 2022.PRINCIPALES MEDIDAS DE RESULTADOS:Caracter&#xed;sticas del paciente y del tumor, tratamiento neoadyuvante y respuesta, recrecimiento local del c&#xe1;ncer y met&#xe1;stasis, cirug&#xed;a de rescate, supervivencia general y espec&#xed;fica de la enfermedad.RESULTADOS:Entre 545 pacientes de 33 centros, el seguimiento fue de 21 meses (rango, 9-37). Se utiliz&#xf3; terapia neoadyuvante total u otros tipos de neoadyuvancia en 395 (72%) y 150 (28%) de los pacientes, respectivamente. La tasa estimada de recrecimiento local a 3 a&#xf1;os fue del 23,8% (IC del 95%: 19,1-29,4%). Los pacientes con recrecimiento local tuvieron una mayor incidencia de met&#xe1;stasis a distancia (14,2% frente a 3,5%, p &lt; 0,001). Se realiz&#xf3; cirug&#xed;a de rescate en 74/84 (88%) pacientes con recrecimiento local e incluy&#xf3; resecci&#xf3;n rectal en 66 (89%) y escisi&#xf3;n local en 8 (11%). De 64 resecciones de rescate con resultados patol&#xf3;gicos conocidos, 58 (91%) fueron m&#xe1;rgenes negativos. En general, la supervivencia global a los 3 a&#xf1;os fue del 94,8 % (IC del 95 %: 90,5-97,2 %) y la supervivencia espec&#xed;fica de la enfermedad a los 3 a&#xf1;os del 96,2 % (IC del 95 %: 91,8-98,2 %). Los pacientes con y sin recrecimiento local mostraron una supervivencia global a los 3 a&#xf1;os del 83,6 % (IC del 95 %: 68,4-91,9 %) y del 97,7 % (IC del 95 %: 93,3-99,2 %), respectivamente.LIMITACIONES:Estudio retrospectivo.CONCLUSI&#xd3;N:Este estudio multic&#xe9;ntrico indica que el enfoque de observaci&#xf3;n y espera para el c&#xe1;ncer rectal localmente avanzado es factible con resultados aceptables en una variedad de regiones geogr&#xe1;ficas y entornos de pr&#xe1;ctica en los EE. UU. Las tasas de recrecimiento local y met&#xe1;stasis a distancia estuvieron dentro de las normas publicadas y la cirug&#xed;a de rescate result&#xf3; eficaz. (Traducci&#xf3;n-Dr Yolanda Colorado ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Samuel H</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0003-0187-4255</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Widmar</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monson</LastName><ForeName>John R T</ForeName><Initials>JRT</Initials><AffiliationInfo><Affiliation>Northwell Health, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleming</LastName><ForeName>Fergal J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Rochester Medical Center, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Arden M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Jon D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>US Rectal Cancer Research Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057832" MajorTopicYN="Y">Watchful Waiting</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016879" MajorTopicYN="N">Salvage Therapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="ANTECEDENTES:">El uso de una estrategia de manejo de observaci&#xf3;n y espera despu&#xe9;s de una respuesta cl&#xed;nica completa a la terapia neoadyuvante para el c&#xe1;ncer de recto est&#xe1; aumentando. Sin embargo, los conocimientos sobre la implementaci&#xf3;n, los tratamientos y los resultados, a nivel nacional de los Estados Unidos, son limitados.</AbstractText><AbstractText Label="OBJETIVO:">Investigar e informar sobre las pr&#xe1;cticas y los resultados del manejo de observaci&#xf3;n y espera en los EE. UU.</AbstractText><AbstractText Label="DISE&#xd1;O:">Estudio retrospectivo.</AbstractText><AbstractText Label="ESCENARIO:">Multic&#xe9;ntrico.</AbstractText><AbstractText Label="PACIENTES:">Pacientes con c&#xe1;ncer de recto en estadio II o III que se sometieron a un manejo de observaci&#xf3;n y espera intencional entre enero de 2015 y agosto de 2022.</AbstractText><AbstractText Label="PRINCIPALES MEDIDAS DE RESULTADOS:">Caracter&#xed;sticas del paciente y del tumor, tratamiento neoadyuvante y respuesta, recrecimiento local del c&#xe1;ncer y met&#xe1;stasis, cirug&#xed;a de rescate, supervivencia general y espec&#xed;fica de la enfermedad.</AbstractText><AbstractText Label="RESULTADOS:">Entre 545 pacientes de 33 centros, el seguimiento fue de 21 meses (rango, 9&#x2013;37). Se utiliz&#xf3; terapia neoadyuvante total u otros tipos de neoadyuvancia en 395 (72%) y 150 (28%) de los pacientes, respectivamente. La tasa estimada de recrecimiento local a 3 a&#xf1;os fue del 23,8% (IC del 95%: 19,1&#x2013;29,4%). Los pacientes con recrecimiento local tuvieron una mayor incidencia de met&#xe1;stasis a distancia (14,2% frente a 3,5%, p &lt; 0,001). Se realiz&#xf3; cirug&#xed;a de rescate en 74/84 (88%) pacientes con recrecimiento local e incluy&#xf3; resecci&#xf3;n rectal en 66 (89%) y escisi&#xf3;n local en 8 (11%). De 64 resecciones de rescate con resultados patol&#xf3;gicos conocidos, 58 (91%) fueron m&#xe1;rgenes negativos. En general, la supervivencia global a los 3 a&#xf1;os fue del 94,8 % (IC del 95 %: 90,5&#x2013;97,2 %) y la supervivencia espec&#xed;fica de la enfermedad a los 3 a&#xf1;os del 96,2 % (IC del 95 %: 91,8&#x2013;98,2 %). Los pacientes con y sin recrecimiento local mostraron una supervivencia global a los 3 a&#xf1;os del 83,6 % (IC del 95 %: 68,4&#x2013;91,9 %) y del 97,7 % (IC del 95 %: 93,3&#x2013;99,2 %), respectivamente.</AbstractText><AbstractText Label="LIMITACIONES:">Estudio retrospectivo.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N:">Este estudio multic&#xe9;ntrico indica que el enfoque de observaci&#xf3;n y espera para el c&#xe1;ncer rectal localmente avanzado es factible con resultados aceptables en una variedad de regiones geogr&#xe1;ficas y entornos de pr&#xe1;ctica en los EE. UU. Las tasas de recrecimiento local y met&#xe1;stasis a distancia estuvieron dentro de las normas publicadas y la cirug&#xed;a de rescate result&#xf3; eficaz. <i>(Pre-proofed version)</i></AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></OtherAbstract><InvestigatorList><Investigator ValidYN="Y"><LastName>Gupta</LastName><ForeName>Abhinav</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Price</LastName><ForeName>Adam D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Booth</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flores</LastName><ForeName>Aileen De Mucha</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khan</LastName><ForeName>Aimal</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fichera</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hawkins</LastName><ForeName>Alexander T</ForeName><Initials>AT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayman</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fa</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuhnen</LastName><ForeName>Angela H</ForeName><Initials>AH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melio</LastName><ForeName>Anna A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fabrizio</LastName><ForeName>Anne C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loria</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villano</LastName><ForeName>Anthony M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caycedo-Marulanda</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Arden</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amir</LastName><ForeName>Arslan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duby</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shogan</LastName><ForeName>Benjamin D</ForeName><Initials>BD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosamond</LastName><ForeName>Brendan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Brian N</ForeName><Initials>BN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monahan</LastName><ForeName>Brian V</ForeName><Initials>BV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newton</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hong</LastName><ForeName>Christine L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aquina</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munroe</LastName><ForeName>Cody</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donahue</LastName><ForeName>Colleen A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayden</LastName><ForeName>Dana M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kleiman</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>David D Q</ForeName><Initials>DDQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dietz</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keller</LastName><ForeName>Deborah S</ForeName><Initials>DS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strungs</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flemming</LastName><ForeName>Fergal</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romero-Hernandez</LastName><ForeName>Fernanda</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saidi</LastName><ForeName>Hela</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Govekar</LastName><ForeName>Henry R</ForeName><Initials>HR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paquette</LastName><ForeName>Ian M</ForeName><Initials>IM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klausner</LastName><ForeName>Jake</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Jeanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farma</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller-Ocuin</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rytych</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knight</LastName><ForeName>Jimmie</ForeName><Initials>J</Initials><Suffix>3rd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Marks M D</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monson</LastName><ForeName>John R T</ForeName><Initials>JRT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vogel</LastName><ForeName>Jon</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abelson</LastName><ForeName>Jonathan S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohn</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wells</LastName><ForeName>Katerina K O</ForeName><Initials>KKO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akemi Tavares</LastName><ForeName>Kelli Beth</ForeName><Initials>KB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cologne</LastName><ForeName>Kyle G</ForeName><Initials>KG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Temple</LastName><ForeName>Larissa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bustamente-Lopez</LastName><ForeName>Leo</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Force</LastName><ForeName>Luanne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varma</LastName><ForeName>Madhulika G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrara</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Widmar</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whiteford</LastName><ForeName>Mark H</ForeName><Initials>MH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalady</LastName><ForeName>Matthew F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hill</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>Melissa I</ForeName><Initials>MI</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGee</LastName><ForeName>Michael F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matos</LastName><ForeName>Monique C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Piyush</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aoun</LastName><ForeName>Rami James N</ForeName><Initials>RJN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daugherty</LastName><ForeName>Ray S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cleary</LastName><ForeName>Robert K</ForeName><Initials>RK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guevara</LastName><ForeName>Salvador G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Younan</LastName><ForeName>Samuel A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lai</LastName><ForeName>Samuel H</ForeName><Initials>SH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boatman</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greco</LastName><ForeName>Stephanie H</ForeName><Initials>SH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russell</LastName><ForeName>Tara A</ForeName><Initials>TA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prasad Poola</LastName><ForeName>Taylor Penn V</ForeName><Initials>TPV</Initials></Investigator><Investigator ValidYN="Y"><LastName>George</LastName><ForeName>Virgilio V</ForeName><Initials>VV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poylin</LastName><ForeName>Vitaliy Y</ForeName><Initials>VY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simianu</LastName><ForeName>Vlad V</ForeName><Initials>VV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaertner</LastName><ForeName>Wolfgang B</ForeName><Initials>WB</Initials></Investigator><Investigator ValidYN="Y"><LastName>To</LastName><ForeName>Yue-Yun</ForeName><Initials>YY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sun</LastName><ForeName>Zhifei</ForeName><Initials>Z</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>24</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>13</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>7</Day><Hour>8</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39508482</ArticleId><ArticleId IdType="mid">NIHMS2083505</ArticleId><ArticleId IdType="pmc">PMC12232607</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003586</ArticleId><ArticleId IdType="pii">00003453-990000000-00789</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:1139&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">36240850</ArticleId></ArticleIdList></Reference><Reference><Citation>Habr-Gama A, de Souza PM, Ribeiro U Jr, et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum. 1998;41:1087&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">9749491</ArticleId></ArticleIdList></Reference><Reference><Citation>Habr-Gama A, Oliva Perez R, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1356472</ArticleId><ArticleId IdType="pubmed">15383798</ArticleId></ArticleIdList></Reference><Reference><Citation>Langenfeld SJ, Davis BR, Vogel JD, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer 2023 supplement. Dis Colon Rectum. 2024;67:18&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">37647138</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch &amp; Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537&#x2013;2545.</Citation><ArticleIdList><ArticleId IdType="pubmed">29976470</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadi SA, Malcomson L, Ensor J, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:825&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">30318451</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin RI, Schiff JP, Shetty AS, et al. Circumferential resection margin as predictor of nonclinical complete response in nonoperative management of rectal cancer. Dis Colon Rectum. 2023;66:973&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">36876988</ArticleId></ArticleIdList></Reference><Reference><Citation>Dattani M, Heald RJ, Goussous G, et al. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg. 2018;268:955&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">29746338</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40:2546&#x2013;2556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9362876</ArticleId><ArticleId IdType="pubmed">35483010</ArticleId></ArticleIdList></Reference><Reference><Citation>Habr-Gama A, S&#xe3;o Juli&#xe3;o GP, Fernandez LM, et al. Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think! Dis Colon Rectum. 2019;62:802&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">31188180</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Rodriguez RM, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal cancer treated with total neoadjuvant therapy. Dis Colon Rectum. 2021;64:1463&#x2013;1470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820240</ArticleId><ArticleId IdType="pubmed">34508014</ArticleId></ArticleIdList></Reference><Reference><Citation>Rettig RL, Beard BW, Ryoo JJ, et al. Total neoadjuvant therapy significantly increases complete clinical response. Dis Colon Rectum. 2023;66:374&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">35239525</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez LM, S&#xe3;o Juli&#xe3;o GP, Figueiredo NL, et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch &amp; Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol. 2021;22:43&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">33316218</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JJ, Strombom P, Chow OS, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5:e185896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6459120</ArticleId><ArticleId IdType="pubmed">30629084</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez LM, S&#xe3;o Juli&#xe3;o GP, Renehan AG, et al. The risk of distant metastases in patients with clinical complete response managed by watch and wait after neoadjuvant therapy for rectal cancer: the influence of local regrowth in the International Watch and Wait Database. Dis Colon Rectum. 2023;66:41&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">36515514</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman BC, Lai SH, Friedrich T, et al. Rectal cancer: clinical and molecular predictors of a complete response to total neoadjuvant therapy. Dis Colon Rectum. 2023;66:521&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">34984995</ArticleId></ArticleIdList></Reference><Reference><Citation>Loria A, Tejani MA, Temple LK, et al. Practice patterns for organ preservation in US patients with rectal cancer, 2006&#x2013;2020. JAMA Oncol. 2024;10:79&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10636650</ArticleId><ArticleId IdType="pubmed">37943566</ArticleId></ArticleIdList></Reference><Reference><Citation>Sammour T, Price BA, Krause KJ, Chang GJ. Nonoperative management or &#x2018;watch and wait&#x2019; for rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy: a critical appraisal. Ann Surg Oncol. 2017;24:1904&#x2013;1915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6106774</ArticleId><ArticleId IdType="pubmed">28324284</ArticleId></ArticleIdList></Reference><Reference><Citation>Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:501&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">28479372</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai S, Widmar M, Monson J, Morris A, Fleming F, Vogel J. Rectal cancer watch &amp; wait strategy: the U.S. Rectal Cancer Research Group experience with 545 patients [ASCRS abstract T103]. Dis Colon Rectum. 2024;67:e504&#x2013;e505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12232607</ArticleId><ArticleId IdType="pubmed">39508482</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39508468</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Long-term Follow-up After an Initial Episode of Diverticulitis: A 13-Year Update.</ArticleTitle><Pagination><StartPage>234</StartPage><EndPage>241</EndPage><MedlinePgn>234-241</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003587</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">For patients with recurrent diverticulitis, the trigger to proceed to elective sigmoid colectomy is unclear. Current clinical practice guidelines suggest that this is an individualized decision between surgeon and patient.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the long-term risk of diverticulitis recurrence and determine predictors of recurrent disease.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective case series.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Tertiary care center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Consecutive patients with CT-proven diverticulitis who presented as inpatient or outpatient between 2002 and 2008.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Incidence of diverticulitis recurrence was determined via medical record review and questionnaire.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Risk of recurrent diverticulitis or surgery for diverticulitis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 753 patients with first-time diverticulitis were identified. The patients had a mean age of 61.5 years (SD 15.3). The median follow-up was 13.2 years (interquartile range, 3.8-18.3). There were 486 patients (64.5%) alive at the time of follow-up. During the initial presentation, 29 patients (3.9%) required Interventional Radiology drainage and 37 (4.9%) required emergency surgery. Forty-three patients (5.7%) underwent elective surgery after the initial presentation and 77 (10.2%) underwent surgery after more than 1 episode. Of those who did not undergo surgery for the first episode, 353 (52.4%) experienced recurrent disease with a median time to recurrence of 2.9 years (interquartile range, 0.83-8.5 years). On multivariate analysis, female sex (HR 1.28, p = 0.04), sigmoid disease (HR 1.35, p = 0.03), smoldering disease (HR 3.17, p &lt; 0.01), length of involved segment &gt;5&#x2009;cm (HR 1.28, p = 0.04), and maximum fat stranding diameter &gt;1.8&#x2009;cm (HR 1.29, p = 0.03) were associated with disease recurrence. Kaplan-Meier estimates of freedom from recurrence were 73.1% (69.6%-76.3%) at 1 year, 47.9% (44.0%-51.6%) at 5 years, and 34.6% (31.0%-38.2%) at 10 years after initial presentation.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective design.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">After a single episode of diverticulitis, the incidence of recurrence is more than 50% on long-term follow-up. Variables such as female sex, sigmoid disease, smoldering disease, length of involved segment &gt;5&#x2009;cm, and maximum fat stranding diameter &gt;1.8&#x2009;cm were associated with an increased risk of recurrence. These findings should be considered when counseling patients on the decision to proceed with elective colectomy. See Video Abstract .</AbstractText><AbstractText Label="SEGUIMIENTO A LARGO PLAZO TRAS UN EPISODIO INICIAL DE DIVERTICULITIS UNA ACTUALIZACIN DE AOS" NlmCategory="UNASSIGNED">ANTECEDENTES:En el caso de los pacientes con diverticulitis recurrente, no est&#xe1; claro el factor desencadenante para proceder a una colectom&#xed;a sigmoidea electiva. Las gu&#xed;as de pr&#xe1;ctica cl&#xed;nica actuales sugieren que se trata de una decisi&#xf3;n individualizada entre el cirujano y el paciente.OBJETIVO:Evaluar el riesgo a largo plazo de recurrencia de la diverticulitis y determinar los predictores de la enfermedad recurrente.DISE&#xd1;O:Serie de casos retrospectiva.ESCENARIO:Centro de atenci&#xf3;n terciaria.PACIENTES:Pacientes consecutivos con diverticulitis comprobada por TC que se presentaron como pacientes hospitalizados o ambulatorios entre 2002 y 2008.INTERVENCIONES:Incidencia de recurrencia de la diverticulitis determinada mediante revisi&#xf3;n de historias cl&#xed;nicas y cuestionario.MEDIDAS PRINCIPALES DE RESULTADOS:Riesgo de diverticulitis recurrente o cirug&#xed;a para diverticulitis.RESULTADOS:Se identificaron 753 pacientes con diverticulitis por primera vez. Los pacientes ten&#xed;an 61,5 a&#xf1;os (DE 15,3). La mediana de seguimiento fue de 13,2 a&#xf1;os (RIC 3,8-18,3). 486 (64,5 %) estaban vivos en el momento del seguimiento. Durante la presentaci&#xf3;n inicial, 29 (3,9 %) requirieron drenaje de IR y 37 (4,9 %) requirieron cirug&#xed;a de emergencia. 43 (5,7 %) se sometieron a cirug&#xed;a electiva despu&#xe9;s de la presentaci&#xf3;n inicial y 77 (10,2 %) se sometieron a cirug&#xed;a despu&#xe9;s de m&#xe1;s de 1 episodio. De aquellos sin cirug&#xed;a para el primer episodio, 353 (52,4 %) experimentaron enfermedad recurrente con un tiempo medio hasta la recurrencia de 2,9 a&#xf1;os (RIC 0,83-8,5 a&#xf1;os). En el an&#xe1;lisis multivariable, el sexo femenino (HR 1,28, p = 0,04), la enfermedad sigmoidea (HR 1,35, p = 0,03), la enfermedad latente (HR 3,17, p &lt; 0,01), la longitud del segmento afectado &gt; 5&#x2009;cm (HR 1,28, p = 0,04) y el di&#xe1;metro m&#xe1;ximo de la hebra grasa &gt; 1,8&#x2009;cm (HR 1,29, p = 0,03) se asociaron con la recurrencia de la enfermedad. Las estimaciones de Kaplan Meier de la libertad de recurrencia fueron del 73,1 % (69,6-76,3 %) al a&#xf1;o, del 47,9 % (44,0-51,6 %) a los 5 a&#xf1;os y del 34,6 % (31,0-38,2 %) a los 10 a&#xf1;os despu&#xe9;s de la presentaci&#xf3;n inicial.LIMITACIONES:Dise&#xf1;o retrospectivo.CONCLUSIONES:Despu&#xe9;s de un &#xfa;nico episodio de diverticulitis, la incidencia de recurrencia es superior al 50% en el seguimiento a largo plazo. Variables como el sexo femenino, la enfermedad sigmoidea, la enfermedad latente, la longitud del segmento afectado mayor de 5&#x2009;cm y el di&#xe1;metro m&#xe1;ximo de la hebra de grasa mayor de 1,8&#x2009;cm se asociaron con un mayor riesgo de recurrencia. Estos hallazgos deben tenerse en cuenta al asesorar a los pacientes sobre la decisi&#xf3;n de proceder con la colectom&#xed;a electiva. (Traducci&#xf3;n-Yesenia Rojas-Khalil ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anwar</LastName><ForeName>Sarah N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dombek</LastName><ForeName>Gabrielle E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>Caroline E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>Maggie J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munroe</LastName><ForeName>Cody</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abelson</LastName><ForeName>Jonathan S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Jason F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Tufts University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleiman</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhnen</LastName><ForeName>Angela H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcello</LastName><ForeName>Peter W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0003-2014-0302</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>NA</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="Y">Colectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004239" MajorTopicYN="Y">Diverticulitis, Colonic</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017558" MajorTopicYN="N">Elective Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>24</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>13</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>7</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39508468</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003587</ArticleId><ArticleId IdType="pii">00003453-990000000-00790</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carr S, Velasco AL. Colon Diverticulitis. Treasure Island, FL: StatPearls; 2024.</Citation></Reference><Reference><Citation>Roberts P, Abel M, Rosen L, et al. Practice parameters for sigmoid diverticulitis. The standards Task Force American Society of Colon and Rectal Surgeons. Dis Colon Rectum. 1995;38:125&#x2013;132.</Citation></Reference><Reference><Citation>Hall J, Hardiman K, Lee S, et al.; Prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of left-sided colonic diverticulitis. Dis Colon Rectum. 2020;63:728&#x2013;747.</Citation></Reference><Reference><Citation>Santos A, Mentula P, Pinta T, et al. Quality-of-life and recurrence outcomes following laparoscopic elective sigmoid resection vs conservative treatment following diverticulitis: prespecified 2-year analysis of the LASER randomized clinical trial. JAMA Surg. 2023;158:593&#x2013;601.</Citation></Reference><Reference><Citation>Makela J, Vuolio S, Kiviniemi H, Laitinen S. Natural history of diverticular disease: when to operate? Dis Colon Rectum. 1998;41:1523&#x2013;1528.</Citation></Reference><Reference><Citation>Broderick-Villa G, Burchette RJ, Collins JC, Abbas MA, Haigh PI. Hospitalization for acute diverticulitis does not mandate routine elective colectomy. Arch Surg. 2005;140:576&#x2013;581.</Citation></Reference><Reference><Citation>Hall JF, Roberts PL, Ricciardi R, et al. Long-term follow-up after an initial episode of diverticulitis: what are the predictors of recurrence? Dis Colon Rectum. 2011;54:283&#x2013;288.</Citation></Reference><Reference><Citation>Mathilde A, Mege D, Monsinjon M, Giacca M, Panis Y. Recurrence of diverticulitis after prophylactic sigmoidectomy: an underestimated problem? Colorectal Dis. 2023;25:757&#x2013;763.</Citation></Reference><Reference><Citation>Waser A, Balaphas A, Uhe I, et al. Incidence of diverticulitis recurrence after sigmoid colectomy: a retrospective cohort study from a tertiary center and systematic review. Int J Colorectal Dis. 2023;38:157.</Citation></Reference><Reference><Citation>Salusjarvi JM, Koskenvuo LE, Mali JP, Mentula PJ, Leppaniemi AK, Sallinen VJ. Stoma reversal after Hartmann&#x2019;s procedure for acute diverticulitis. Surgery. 2023;173:920&#x2013;926.</Citation></Reference><Reference><Citation>Anwar S, Dombek GE, Hayes C. Long-term follow-up after an initial episode of diverticulitis: a 15 year update (ASCRS abstract #SA203). Dis Colon Rectum. 2024;67:e399&#x2013;e400.</Citation></Reference><Reference><Citation>Bharucha AE, Parthasarathy G, Ditah I, et al. Temporal trends in the incidence and natural history of diverticulitis: a population-based study. Am J Gastroenterol. 2015;110:1589&#x2013;1596.</Citation></Reference><Reference><Citation>Eglinton T, Nguyen T, Raniga S, Dixon L, Dobbs B, Frizelle FA. Patterns of recurrence in patients with acute diverticulitis. Br J Surg. 2010;97:952&#x2013;957.</Citation></Reference><Reference><Citation>Binda GA, Arezzo A, Serventi A, et al.; Italian Study Group on Complicated Diverticulosis (GISDIC). Multicentre observational study of the natural history of left-sided acute diverticulitis. Br J Surg. 2012;99:276&#x2013;285.</Citation></Reference><Reference><Citation>Rose J, Parina RP, Faiz O, Chang DC, Talamini MA. Long-term outcomes after initial presentation of diverticulitis. Ann Surg. 2015;262:1046&#x2013;1053.</Citation></Reference><Reference><Citation>Ho VP, Nash GM, Milsom JW, Lee SW. Identification of diverticulitis patients at high risk for recurrence and poor outcomes. J Trauma Acute Care Surg. 2015;78:112&#x2013;119.</Citation></Reference><Reference><Citation>Garfinkle R, Almalki T, Pelsser V, et al. Conditional risk of diverticulitis after non-operative management. Br J Surg. 2020;107:1838&#x2013;1845.</Citation></Reference><Reference><Citation>Choi KK, Martinolich J, Canete JJ, et al. Elective laparoscopic sigmoid colectomy for diverticulitis&#x2014;an updated look at recurrence after surgery. J Gastrointest Surg. 2020;24:388&#x2013;395.</Citation></Reference><Reference><Citation>Mizrahi I, Al-Kurd A, Chapchay K, et al. Long-term outcomes of sigmoid diverticulitis: a single-center experience. J Surg Res. 2018;221:8&#x2013;14.</Citation></Reference><Reference><Citation>Boostrom SY, Wolff BG, Cima RR, Merchea A, Dozois EJ, Larson DW. Uncomplicated diverticulitis, more complicated than we thought. J Gastrointest Surg. 2012;16:1744&#x2013;1749.</Citation></Reference><Reference><Citation>Wolff BG, Boostrom SY. Prophylactic resection, uncomplicated diverticulitis, and recurrent diverticulitis. Dig Dis. 2012;30:108&#x2013;113.</Citation></Reference><Reference><Citation>Lane JS, Sarkar R, Schmit PJ, Chandler CF, Thompson JE Jr. Surgical approach to cecal diverticulitis. J Am Coll Surg. 1999;188:629&#x2013;634.</Citation></Reference><Reference><Citation>Sung CW, Liu KL, Wang HP, et al. Author Correction: Colonic diverticulitis location is a risk factor for recurrence: a multicenter, retrospective cohort study in Asian patients. Sci Rep. 2022;12:13254.</Citation></Reference><Reference><Citation>Oh MY, Shin R, Heo SC, et al. Investigation of the clinical features and recurrence patterns of acute right-sided colonic diverticulitis: a retrospective cohort study. Ann Med Surg (Lond). 2022;81:104431.</Citation></Reference><Reference><Citation>Dickerson EC, Chong ST, Ellis JH, et al. Recurrence of colonic diverticulitis: identifying predictive CT findings-retrospective cohort study. Radiology. 2017;285:850&#x2013;858.</Citation></Reference><Reference><Citation>Poletti PA, Platon A, Rutschmann O, et al. Acute left colonic diverticulitis: can CT findings be used to predict recurrence? AJR Am J Roentgenol. 2004;182:1159&#x2013;1165.</Citation></Reference><Reference><Citation>Kim DH, Kim HJ, Jang SK, Yeon JW, Shin KS. CT predictors of unfavorable clinical outcomes of acute right colonic diverticulitis. Am J Roentgenol. 2017;209:1263&#x2013;1271.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35239529</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Rectal Prolapse Pathological Features: Findings in Patients With Outlet Obstruction Treated With Stapled Transanal Rectal Resection.</ArticleTitle><Pagination><StartPage>e826</StartPage><EndPage>e833</EndPage><MedlinePgn>e826-e833</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002269</ELocationID><Abstract><AbstractText Label="BACKGROUND">Obstructed defecation syndrome is a common multifactorial disease for which treatment is based primarily on clinic presentation for the lack of reliable instrumental and anatomopathological criteria.</AbstractText><AbstractText Label="OBJECTIVE">The study aimed to analyze the pathological findings of the resected rectal specimens after stapled transanal rectal resection in patients affected by outlet obstruction.</AbstractText><AbstractText Label="DESIGN">Retrospective cohort study.</AbstractText><AbstractText Label="SETTINGS">University hospital.</AbstractText><AbstractText Label="PATIENTS">Patients who underwent rectal resection for obstructed defecation syndrome due to internal rectal prolapse were included.</AbstractText><AbstractText Label="INTERVENTIONS">Specimens of patients with obstructed defecation syndrome were analyzed through conventional histology and morphometric image analysis and compared with those of rectal specimens excised for oncological diseases.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Analysis of the anatomopathological impairments underlying rectal prolapse.</AbstractText><AbstractText Label="RESULTS">From January 2017 to December 2020, 46 specimens from the stapled transanal rectal resection group were compared with 40 specimens from the control group. In the stapled transanal rectal resection group, conventional histology revealed 34 samples (73.9%) had moderate- to severe-grade fibrosis with moderate-grade nerve degeneration in 33 cases (71.7%). In the control group, conventional histology revealed the absence of fibrosis in 31 specimens (77.5%), whereas the absence of nerve degeneration was detected in 37 specimens (92.5%). In the stapled transanal rectal resection group, morphometric image analysis showed severe-grade fibrosis in 25 cases (54.4%) compared to only low-grade fibrosis in 11 cases (27.5%).</AbstractText><AbstractText Label="LIMITATIONS">The small sample size and the retrospective design of the study were limitations. Moreover, there was no chance to use specimens from healthy volunteers as the control group.</AbstractText><AbstractText Label="CONCLUSIONS">Stapled transanal rectal resection specimens showed a higher rate of fibrosis and nerve dysplasia, an important parameter that is typically not considered preoperatively and could lead patients with rectal prolapse to the best treatment approach. See Video Abstract at http://links.lww.com/DCR/B928 .</AbstractText><AbstractText Label="CARACTERSTICAS ANATOMOPATOLGICAS EN EL PROLAPSO DE RECTO HALLAZGOS EN PACIENTES CON OBSTRUCCIN DEL TRACTO DE SALIDA TRATADOS CON RESECCIN RECTAL TRANSANAL CON GRAPAS">ANTECEDENTES:El s&#xed;ndrome de obstrucci&#xf3;n del tracto de salida, es una afecci&#xf3;n multifactorial com&#xfa;n, cuyo tratamiento est&#xe1; basado principalmente en la presentaci&#xf3;n cl&#xed;nica, &#xe9;sto, debido a la falta de criterios confiables tanto instrumentales como anatomopatol&#xf3;gicos.OBJETIVO:Analizamos los hallazgos histopatol&#xf3;gicos de las piezas de resecci&#xf3;n rectal obtenidas por v&#xed;a transanal mediante grapas, realizadas en pacientes que presentaban obstrucci&#xf3;n del tracto de salida.DISE&#xd1;O:Este fue un estudio de cohorte retrospectivo.AJUSTE:El escenario fue un hospital universitario.PACIENTES:Aquellos sometidos a resecci&#xf3;n rectal por s&#xed;ndrome obstructivo del tracto de salida causada por un prolapso rectal interno.INTERVENCIONES:Los espec&#xed;menes de pacientes con s&#xed;ndrome obstructivo defecatorio fueron analizados mediante histolog&#xed;a convencional y an&#xe1;lisis de im&#xe1;genes morfom&#xe9;tricas, comparados con espec&#xed;menes rectales resecados por enfermedad oncol&#xf3;gica.PRINCIPALES MEDIDAS DE RESULTADO:El resultado primario se concentr&#xf3; en la investigaci&#xf3;n de las deficiencias anatomopatol&#xf3;gicas subyacentes del prolapso rectal interno.RESULTADOS:Desde enero de 2017 hasta diciembre de 2020, se compararon 46 espec&#xed;menes del grupo de resecci&#xf3;n rectal transanal con grapas con 40 espec&#xed;menes del grupo de control. En histolog&#xed;a convencional, el grupo de resecci&#xf3;n rectal transanal con grapas, 34 muestras (73,9%) presentaron un grado de fibrosis moderada-severa con un grado moderado de degeneraci&#xf3;n neur&#xf3;gena en 33 casos (71,7%). En el grupo control, la histolog&#xed;a convencional revel&#xf3; ausencia de fibrosis en 31 espec&#xed;menes (77,5 %), mientras que la ausencia de degeneraci&#xf3;n neur&#xf3;gena se detect&#xf3; en 37 controles (92,5 %). En el grupo de resecci&#xf3;n rectal transanal con grapas, el an&#xe1;lisis de im&#xe1;genes morfom&#xe9;tricas mostr&#xf3; fibrosis moderada y fibrosis severa en 19 (41,3%) y 25 (54,4%) casos, respectivamente. En el grupo control, el an&#xe1;lisis de im&#xe1;genes morfom&#xe9;tricas mostr&#xf3; solo un bajo grado de fibrosis en 11 casos (27,5%). Se encontr&#xf3; una diferencia significativa en todos los grados de fibrosis y displasia neur&#xf3;gena entre los grupos en las evaluaciones de an&#xe1;lisis de imagen morfom&#xe9;trica e histolog&#xed;a convencional (p &lt; 0,001).LIMITACIONES:El peque&#xf1;o tama&#xf1;o de la muestra y el dise&#xf1;o retrospectivo del estudio. Adem&#xe1;s, no existe la posibilidad de utilizar un grupo de control con muestras de voluntarios sanos.CONCLUSIONES:Los espec&#xed;menes de resecci&#xf3;n rectal transanal con grapas mostraron una mayor tasa de fibrosis y displasia neur&#xf3;gena, par&#xe1;metro importante que actualmente no est&#xe1; considerado antes de la operaci&#xf3;n y en un futuro muy cercano podr&#xed;a orientar a los pacientes con prolapso rectal interno hacia un mejor enfoque de tratamiento. Consulte Video Resumen en http://links.lww.com/DCR/B928 . (Traducci&#xf3;n-Dr. Xavier Delgadillo ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brusciano</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of General, Oncologic, Mininvasive and Bariatric Surgery, University of Campania "Luigi Vanvitelli," Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gambardella</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of General, Oncologic, Mininvasive and Bariatric Surgery, University of Campania "Luigi Vanvitelli," Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falato</LastName><ForeName>Armando</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of General, Oncologic, Mininvasive and Bariatric Surgery, University of Campania "Luigi Vanvitelli," Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ronchi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pathology Unit, University of Campania "Luigi Vanvitelli," Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tolone</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of General, Oncologic, Mininvasive and Bariatric Surgery, University of Campania "Luigi Vanvitelli," Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucido</LastName><ForeName>Francesco S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Division of General, Oncologic, Mininvasive and Bariatric Surgery, University of Campania "Luigi Vanvitelli," Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Genio</LastName><ForeName>Gianmattia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of General, Oncologic, Mininvasive and Bariatric Surgery, University of Campania "Luigi Vanvitelli," Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gualtieri</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of General, Oncologic, Mininvasive and Bariatric Surgery, University of Campania "Luigi Vanvitelli," Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terracciano</LastName><ForeName>Gianmattia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of General, Oncologic, Mininvasive and Bariatric Surgery, University of Campania "Luigi Vanvitelli," Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Docimo</LastName><ForeName>Ludovico</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of General, Oncologic, Mininvasive and Bariatric Surgery, University of Campania "Luigi Vanvitelli," Naples, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012005" MajorTopicYN="Y">Rectal Prolapse</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006785" MajorTopicYN="N">Hospitals, University</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35239529</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002269</ArticleId><ArticleId IdType="pii">00003453-202308000-00015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rao SS, Bharucha AE, Chiarioni G, et al. Functional anorectal disorders. Gastroenterology. 2016;25:1430&#x2013;1442.e4.</Citation></Reference><Reference><Citation>Madoff RD, Mellgren A. One hundred years of rectal prolapse surgery. Dis Colon Rectum. 1999;42:441&#x2013;450.</Citation></Reference><Reference><Citation>Bachoo P, Brazzelli M, Grant A. Surgery for complete rectal prolapse in adults. Cochrane Database Syst Rev. 2000;(2):CD001758.</Citation></Reference><Reference><Citation>Sailer M, B&#xf6;nicke L, Petersen S. Surgical options in the treatment of rectal prolapse: indications, techniques and results [in German]. Zentralbl Chir. 2007;132:350&#x2013;357.</Citation></Reference><Reference><Citation>Senapati A, Gray RG, Middleton LJ, et al.; PROSPER Collaborative Group. PROSPER: a randomised comparison of surgical treatments for rectal prolapse. Colorectal Dis. 2013;15:858&#x2013;868.</Citation></Reference><Reference><Citation>Boccasanta P, Rosati R, Venturi M, et al. Surgical treatment of complete rectal prolapse: results of abdominal and perineal approaches. J Laparoendosc Adv Surg Tech A. 1999;9:235&#x2013;238.</Citation></Reference><Reference><Citation>Liberman H, Hughes C, Dippolito A. Evaluation and outcome of the Delorme procedure in the treatment of rectal outlet obstruction. Dis Colon Rectum. 2000;43:188&#x2013;192.</Citation></Reference><Reference><Citation>Longo A. Treatment of haemorrhoidal disease by reduction of mucosa and haemorrhoidal prolapse with a circular stapling device: a new procedure. In: 6th World Congress of Endoscopic Surgery. Bologna, Monduzzi, Hagerstown, MD 1998:777&#x2013;784.</Citation></Reference><Reference><Citation>Heriot AG, Skull A, Kumar D. Functional and physiological outcome following transanal repair of rectocele. Br J Surg. 2004;91:1340&#x2013;1344.</Citation></Reference><Reference><Citation>Bock S, Wolff K, Marti L, Schmied BM, Hetzer FH. Long-term outcome after transanal rectal resection in patients with obstructed defecation syndrome. Dis Colon Rectum. 2013;56:246&#x2013;252.</Citation></Reference><Reference><Citation>Ding JH, Zhang B, Bi LX, Yin SH, Zhao K. Functional and morphologic outcome after stapled transanal rectal resection for obstructed defecation syndrome. Dis Colon Rectum. 2011;54:418&#x2013;424.</Citation></Reference><Reference><Citation>Renzi A, Brillantino A, Di Sarno G, Izzo D, D&#x2019;Aniello F, Falato A. Improved clinical outcomes with a new contour-curved stapler in the surgical treatment of obstructed defecation syndrome: a mid-term randomized controlled trial. Dis Colon Rectum. 2011;54:736&#x2013;742.</Citation></Reference><Reference><Citation>Stuto A, Renzi A, Carriero A, et al. Stapled trans-anal rectal resection (STARR) in the surgical treatment of the obstructed defecation syndrome: results of STARR Italian Registry. Surg Innov. 2011;18:248&#x2013;253.</Citation></Reference><Reference><Citation>Duthie GS, Bartolo DC. Abdominal rectopexy for rectal prolapse: a comparison of techniques. Br J Surg. 1992;79:107&#x2013;113.</Citation></Reference><Reference><Citation>Albayati S, Chen P, Morgan MJ, Toh JWT. Robotic vs. laparoscopic ventral mesh rectopexy for external rectal prolapse and rectal intussusception: a systematic review. Tech Coloproctol. 2019;23:529&#x2013;535.</Citation></Reference><Reference><Citation>Brusciano L, Tolone S, Limongelli P, et al. Anatomical and functional features of the internal rectal prolapse with outlet obstruction determined with 3D endorectal ultrasonography and high-resolution anorectal manometry: an observational case-control study. Am J Gastroenterol. 2018;113:1247&#x2013;1250.</Citation></Reference><Reference><Citation>Zorenkov D, Otto S, B&#xf6;ttner M, et al. Morphological alterations of the enteric nervous system in young male patients with rectal prolapse. Int J Colorectal Dis. 2011;26:1483&#x2013;1491.</Citation></Reference><Reference><Citation>Bassotti G, Villanacci V, Bellomi A, et al. An assessment of enteric nervous system and estroprogestinic receptors in obstructed defecation associated with rectal intussusception. Neurogastroenterol Motil. 2012;24:e155&#x2013;e161.</Citation></Reference><Reference><Citation>Agachan F, Chen T, Pfeifer J, Reissman P, Wexner SD. A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum. 1996;39:681&#x2013;685.</Citation></Reference><Reference><Citation>Ribaric G, D&#x2019;Hoore A, Schiffhorst G, Hempel E; TRANSTAR Registry Study Group. STARR with CONTOUR&#xae; TRANSTAR&#x2122; device for obstructed defecation syndrome: one-year real-world outcomes of the European TRANSTAR registry. Int J Colorectal Dis. 2014;29:611&#x2013;622.</Citation></Reference><Reference><Citation>Brusciano L, Limongelli P, Tolone S, et al. Technical aspect of stapled transanal rectal resection. From PPH-01 to contour to both: an optional combined approach to treat obstructed defecation? Dis Colon Rectum. 2015;58:817&#x2013;820.</Citation></Reference><Reference><Citation>Staibano S, Rocco A, Mezza E, De Rosa G, Budillon G, Nardone G. Diagnosis of chronic atrophic gastritis by morphometric image analysis. A new method to overcome the confounding effect of the inflammatory infiltrate. J Pathol. 2002;198:47&#x2013;54.</Citation></Reference><Reference><Citation>Rao SS, Welcher KD, Leistikow JS. Obstructive defecation: a failure of rectoanal coordination. Am J Gastroenterol. 1998;93:1042&#x2013;1050.</Citation></Reference><Reference><Citation>Noelting J, Ratuapli SK, Bharucha AE, Harvey DM, Ravi K, Zinsmeister AR. Normal values for high-resolution anorectal manometry in healthy women: effects of age and significance of rectoanal gradient. Am J Gastroenterol. 2012;107:1530&#x2013;1536.</Citation></Reference><Reference><Citation>Grossi U, Carrington EV, Bharucha AE, Horrocks EJ, Scott SM, Knowles CH. Diagnostic accuracy study of anorectal manometry for diagnosis of dyssynergic defecation. Gut. 2016;65:447&#x2013;455.</Citation></Reference><Reference><Citation>Jimenez W, Par&#xe9;s A, Caballer&#xed;a J, et al. Measurement of fibrosis in needle liver biopsies: evaluation of a colorimetric method. Hepatology. 1985;5:815&#x2013;818.</Citation></Reference><Reference><Citation>Zaitoun AM, al Mardini H, Record CO. Quantitative assessment of gastric atrophy using the syntactic structure analysis. J Clin Pathol. 1998;51:895&#x2013;900.</Citation></Reference><Reference><Citation>Masseroli M, O&#x2019;Valle F, And&#xfa;jar M, et al. Design and validation of a new image analysis method for automatic quantification of interstitial fibrosis and glomerular morphometry. Lab Invest. 1998;78:511&#x2013;522.</Citation></Reference><Reference><Citation>Moragas A, Allende H, Sans M. Characteristics of perisinusoidal collagenization in liver cirrhosis: computer-assisted quantitative analysis. Anal Quant Cytol Histol. 1998;20:169&#x2013;177.</Citation></Reference><Reference><Citation>James J, Bosch KS, Aronson DC, Houtkooper JM. Sirius red histophotometry and spectrophotometry of sections in the assessment of the collagen content of liver tissue and its application in growing rat liver. Liver. 1990;10:1&#x2013;5.</Citation></Reference><Reference><Citation>Terra SA, de Arruda Louren&#xe7;&#xe3;o PL, G Silva M, A Miot H, Rodrigues MAM. A critical appraisal of the morphological criteria for diagnosing intestinal neuronal dysplasia type B. Mod Pathol. 2017;30:978&#x2013;985.</Citation></Reference><Reference><Citation>Geramizadeh B, Akbarzadeh E, Izadi B, Foroutan HR, Heidari T. Immunohistochemical study of enteric nervous system in Hirschsprung&#x2019;s disease and intestinal neuronal dysplasia. Histol Histopathol. 2013;28:345&#x2013;351.</Citation></Reference><Reference><Citation>Bernard CE, Gibbons SJ, Gomez-Pinilla PJ, et al. Effect of age on the enteric nervous system of the human colon. Neurogastroenterol Motil. 2009;21:746&#x2013;e46.</Citation></Reference><Reference><Citation>Gomes OA, de Souza RR, Liberti EA. A preliminary investigation of the effects of aging on the nerve cell number in the myenteric ganglia of the human colon. Gerontology. 1997;43:210&#x2013;217.</Citation></Reference><Reference><Citation>B&#xf6;kkerink GMJ, van der Wilt GJ, de Jong D, et al. Value of macrobiopsies and transanal endoscopic microsurgery in the histological work-up of rectal neoplasms: a retrospective study. World J Gastrointest Oncol. 2017;9:251&#x2013;256.</Citation></Reference><Reference><Citation>Mu&#xf1;oz-Navas M, Ruiz R, Marigil MA, Zozaya JM, S&#xe1;nchez L, Conchillo F. Endoscopic macrobiopsy in the diagnosis of Menetrier disease [in Spanish]. Rev Clin Esp. 1984;175:219&#x2013;222.</Citation></Reference><Reference><Citation>Orrom WJ, Bartolo DC, Miller R, Mortensen NJ, Roe AM. Rectopexy is an ineffective treatment for obstructed defecation. Dis Colon Rectum. 1991;34:41&#x2013;46.</Citation></Reference><Reference><Citation>Cadeddu F, Sileri P, Grande M, De Luca E, Franceschilli L, Milito G. Focus on abdominal rectopexy for full-thickness rectal prolapse: meta-analysis of literature. Tech Coloproctol. 2012;16:37&#x2013;53.</Citation></Reference><Reference><Citation>Formijne Jonkers HA, Poierri&#xe9; N, Draaisma WA, Broeders IA, Consten EC. Laparoscopic ventral rectopexy for rectal prolapse and symptomatic rectocele: an analysis of 245 consecutive patients. Colorectal Dis. 2013;15:695&#x2013;699.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35195555</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Germline Cancer Risk Profiles of Patients With Young-Onset Colorectal Cancer: Findings From a Prospective Universal Germline Testing and Telegenetics Program.</ArticleTitle><Pagination><StartPage>531</StartPage><EndPage>542</EndPage><MedlinePgn>531-542</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002347</ELocationID><Abstract><AbstractText Label="BACKGROUND">Colorectal cancer is being increasingly diagnosed in people younger than 50 years. An inheritable cancer predisposition has been reported in 22% of the young-onset cases. Assessment of germline risk is critical for personalized cancer care.</AbstractText><AbstractText Label="OBJECTIVE">The study aimed to implement universal germline cancer risk assessment and testing and to define the germline cancer risk profiles of patients presenting with young-onset disease.</AbstractText><AbstractText Label="DESIGN">This is a prospective cohort study.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a tertiary-referral academic medical center.</AbstractText><AbstractText Label="PATIENTS">This study included newly diagnosed patients presenting to surgical clinics between September 2019 and February 2021 who were treated on a standardized care pathway including the universal germline risk assessment.</AbstractText><AbstractText Label="INTERVENTIONS">Patients received educational material on young-onset disease, genetic testing, and insurance coverage followed by genetic counseling (either remotely by telegenetics or in person). Consenting patients were assessed on a 47-gene common hereditary cancer panel.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome was a proportion of patients with identifiable germline cancer predisposition.</AbstractText><AbstractText Label="RESULTS">Among 500 patients with colorectal cancer, 185 (37%) were 50 years of age or younger (median: 44). A family history was absent for the majority of patients (123; 67%), and in 15 patients, tumors (8.1%) were deficient in DNA mismatch repair. Germline testing was completed in 130 patients (70%); the remainder were pending (7%), deceased (1%), or declined (22%). Pathogenic germline mutations were identified in 25 of 130 (19%) patients: 12 in mismatch repair genes and 13 in other genes. A variant of uncertain significance was found in 23 (18%) patients. Importantly, a pathogenic germline mutation was identified in 12% of the patients without a family history (versus 32% with; p = 0.015) and in 13% of those with proficient mismatch repair colorectal cancers (versus 71% if deficient; p &lt; 0.001).</AbstractText><AbstractText Label="LIMITATIONS">The study is limited by its implementation at a single tertiary academic institution.</AbstractText><AbstractText Label="CONCLUSIONS">One in 5 patients with young-onset disease harbored germline cancer predisposition. This detection rate, coupled with a high level of interest and acceptance from patients and feasibility of implementation, supports universal germline cancer risk assessment in this patient population. See Video Abstract at http://links.lww.com/DCR/B925 .</AbstractText><AbstractText Label="PERFILES DE RIESGO DE CNCER DE LNEA GERMINAL DE PACIENTES CON CNCER COLORRECTAL DE INICIO JOVEN HALLAZGOS DE UN PROGRAMA UNIVERSAL PROSPECTIVO DE PRUEBAS DE LNEA GERMINAL Y TELEGENTICA">ANTECEDENTES:El c&#xe1;ncer colorrectal se diagnostica cada vez m&#xe1;s en personas menores de 50 a&#xf1;os. Se ha informado una predisposici&#xf3;n hereditaria al c&#xe1;ncer en el 22 % de los casos de aparici&#xf3;n temprana. La evaluaci&#xf3;n del riesgo de la l&#xed;nea germinal es fundamental para la atenci&#xf3;n personalizada del c&#xe1;ncer.OBJETIVO:Implementar la evaluaci&#xf3;n y las pruebas universales de riesgo de c&#xe1;ncer de l&#xed;nea germinal, y definir los perfiles de riesgo de c&#xe1;ncer de l&#xed;nea germinal de los pacientes que presentan una enfermedad de aparici&#xf3;n temprana.DISE&#xd1;O:Un estudio de cohorte prospectivo.AJUSTE:Un centro m&#xe9;dico acad&#xe9;mico de referencia terciaria.PACIENTES:Los pacientes reci&#xe9;n diagnosticados que se presentaron en cl&#xed;nicas quir&#xfa;rgicas entre Septiembre de 2019 y Febrero de 2021 fueron tratados en una v&#xed;a de atenci&#xf3;n estandarizada que incluye una evaluaci&#xf3;n de riesgo de l&#xed;nea germinal universal.INTERVENCI&#xd3;N:Los pacientes recibieron material educativo sobre enfermedades de aparici&#xf3;n temprana, pruebas gen&#xe9;ticas y cobertura de seguro, seguido de asesoramiento gen&#xe9;tico (ya sea a distancia por telegen&#xe9;tica o en persona). Los pacientes que dieron su consentimiento fueron evaluados en un panel de c&#xe1;nceres hereditarios comunes de 47 genes.MEDIDA DE RESULTADO PRINCIPAL:Proporci&#xf3;n de pacientes con predisposici&#xf3;n identificable al c&#xe1;ncer de l&#xed;nea germinal.RESULTADOS:Entre 500 pacientes con c&#xe1;ncer colorrectal, 185 (37%) ten&#xed;an 50 a&#xf1;os o menos (mediana: 44). No hab&#xed;a antecedentes familiares en la mayor&#xed;a (123, 67%) y 15 tumores (8,1%) eran deficientes en la reparaci&#xf3;n del desajuste de &#xe1;cido desoxirribonucleico. La prueba de l&#xed;nea germinal se complet&#xf3; en 130 pacientes (70%); el resto estaban pendientes (7%), fallecidos (1%) o declinados (22%). Se identificaron mutaciones patog&#xe9;nicas de la l&#xed;nea germinal en 25 (de 130, 19%) pacientes: 12 en genes de reparaci&#xf3;n de errores de emparejamiento y 13 en otros genes. Se encontr&#xf3; una variante de significado incierto en 23 (18%) pacientes. Es importante se&#xf1;alar que se identific&#xf3; una mutaci&#xf3;n germinal patog&#xe9;nica en el 12% de los pacientes sin antecedentes familiares (frente al 32% con; p = 0,015) y en el 13% de aquellos con c&#xe1;nceres colorrectales competentes en la reparaci&#xf3;n de errores de emparejamiento (frente al 71% si eran deficientes; p &lt; 0,001).LIMITACI&#xd3;N:Implementado en una sola instituci&#xf3;n acad&#xe9;mica terciaria.CONCLUSI&#xd3;N:Uno de cada cinco pacientes con enfermedad de inicio joven albergaba predisposici&#xf3;n al c&#xe1;ncer de l&#xed;nea germinal. Esta tasa de detecci&#xf3;n, junto con un alto nivel de inter&#xe9;s y aceptaci&#xf3;n por parte de los pacientes y la viabilidad de la implementaci&#xf3;n, respaldan la evaluaci&#xf3;n universal del riesgo de c&#xe1;ncer de l&#xed;nea germinal en esta poblaci&#xf3;n de pacientes. Consulte el Video Resumen en http://links.lww.com/DCR/B925 . (Traducci&#xf3;n-Dr. Yesenia Rojas-Khalil ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>You</LastName><ForeName>Y Nancy</ForeName><Initials>YN</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Cancer Genetics Program, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moskowitz</LastName><ForeName>Julie B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Cancer Genetics Program, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>George J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mork</LastName><ForeName>Maureen E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Cancer Genetics Program, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Bigas</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Cancer Genetics Program, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bednarski</LastName><ForeName>Brian K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messick</LastName><ForeName>Craig A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Cancer Genetics Program, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tillman</LastName><ForeName>Matthew M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skibber</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Sa T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kopetz</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilar</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Cancer Genetics Program, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="Y">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062606" MajorTopicYN="N">Tertiary Care Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35195555</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002347</ArticleId><ArticleId IdType="pii">00003453-202304000-00007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Jakubowski CD, Fedewa SA, Davis A, Azad NS. Colorectal cancer in the young: epidemiology, prevention, management. Am Soc Clin Oncol Educ Book. 2020;40:1&#x2013;14.</Citation></Reference><Reference><Citation>You YN, Xing Y, Feig BW, Chang GJ, Cormier JN. Young-onset colorectal cancer: is it time to pay attention? Arch Intern Med. 2012;172:287&#x2013;289.</Citation></Reference><Reference><Citation>Ahnen DJ, Wade SW, Jones WF, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89:216&#x2013;224.</Citation></Reference><Reference><Citation>Bailey CE, Hu CY, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015;150:17&#x2013;22.</Citation></Reference><Reference><Citation>Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68:250&#x2013;281.</Citation></Reference><Reference><Citation>Barry MJ, Davidson K, Mangione CM. US Preventive Services Task Force recommendation statement on screening for colorectal cancer&#x2014;reply. JAMA. 2021;326:1328&#x2013;1329.</Citation></Reference><Reference><Citation>You YN, Lee LD, Deschner BW, Shibata D. Colorectal cancer in the adolescent and young adult population. JCO Oncol Pract. 2020;16:19&#x2013;27.</Citation></Reference><Reference><Citation>The National Comprehensive Cancer Network (NCCN) Guidelines, Colon Cancer. Version 2.2021. Accessed March 15, 2021.</Citation></Reference><Reference><Citation>Stoffel EM, Boland CR. Genetics and genetic testing in hereditary colorectal cancer. Gastroenterology. 2015;149:1191&#x2013;1203.e2.</Citation></Reference><Reference><Citation>Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2015;33:3660&#x2013;3667.</Citation></Reference><Reference><Citation>Dineen S, Lynch PM, Rodriguez-Bigas MA, et al. A prospective six sigma quality improvement trial to optimize universal screening for genetic syndrome among patients with young-onset colorectal cancer. J Natl Compr Canc Netw. 2015;13:865&#x2013;872.</Citation></Reference><Reference><Citation>Stoffel EM, Mangu PB, Gruber SB, et al.; American Society of Clinical Oncology; European Society of Clinical Oncology. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol. 2015;33:209&#x2013;217.</Citation></Reference><Reference><Citation>You YN, Borras E, Chang K, et al. Detection of pathogenic germline variants among patients with advanced colorectal cancer undergoing tumor genomic profiling for precision medicine. Dis Colon Rectum. 2019;62:429&#x2013;437.</Citation></Reference><Reference><Citation>Mork ME, Rodriguez A, Bannon SA, et al. Outcomes of disease-specific next-generation sequencing gene panel testing in adolescents and young adults with colorectal cancer. Cancer Genet. 2019;235-236:77&#x2013;83.</Citation></Reference><Reference><Citation>Limburg PJ, Harmsen WS, Chen HH, et al. Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer. Clin Gastroenterol Hepatol. 2011;9:497&#x2013;502.</Citation></Reference><Reference><Citation>Stoffel EM, Koeppe E, Everett J, et al. Germline genetic features of young individuals with colorectal cancer. Gastroenterology. 2018;154:897&#x2013;905.e1.</Citation></Reference><Reference><Citation>Pearlman R, Frankel WL, Swanson B, et al.; Ohio Colorectal Cancer Prevention Initiative Study Group. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol. 2017;3:464&#x2013;471.</Citation></Reference><Reference><Citation>Rothstein MA. Can genetic nondiscrimination laws save lives? Hastings Cent Rep. 2021;51:6&#x2013;7.</Citation></Reference><Reference><Citation>Moskowitz J, Mork M, Thirumurthi S, et al. A pilot clinical program for young-onset colorectal cancer patients incorporating video-based pretest counseling and tele-genetics followup. Presented at: the annual meeting of the Collaborative Group of Americas on Inherited Gastrointestinal Cancers (CGA-ICG); 2020.</Citation></Reference><Reference><Citation>Invitae Common Hereditary Cancers Panel. Available at: https://www.invitae.com/en/physician/tests/01102/#info-panel-resources . Accessed March 15, 2021.</Citation></Reference><Reference><Citation>Richards S, Aziz N, Bale S, et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405&#x2013;424.</Citation></Reference><Reference><Citation>Moghadasi S, Eccles DM, Devilee P, Vreeswijk MP, van Asperen CJ. Classification and clinical management of variants of uncertain significance in high penetrance cancer predisposition genes. Hum Mutat. 2016;37:331&#x2013;336.</Citation></Reference><Reference><Citation>Goldstein JB, Wu W, Borras E, et al. Can microsatellite status of colorectal cancer be reliably assessed after neoadjuvant therapy? Clin Cancer Res. 2017;23:5246&#x2013;5254.</Citation></Reference><Reference><Citation>Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. Early-onset colorectal cancer in young individuals. Mol Oncol. 2019;13:109&#x2013;131.</Citation></Reference><Reference><Citation>Mork ME, You YN, Ying J, et al. High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. J Clin Oncol. 2015;33:3544&#x2013;3549.</Citation></Reference><Reference><Citation>Yurgelun MB, Kulke MH, Fuchs CS, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol. 2017;35:1086&#x2013;1095.</Citation></Reference><Reference><Citation>Yurgelun MB, Allen B, Kaldate RR, et al. Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. Gastroenterology. 2015;149:604&#x2013;13.e20.</Citation></Reference><Reference><Citation>Chang PY, Chang SC, Wang MC, et al. Pathogenic germline mutations of DNA repair pathway components in early-onset sporadic colorectal polyp and cancer patients. Cancers (Basel). 2020;12:E3560.</Citation></Reference><Reference><Citation>Dharwadkar P, Greenan G, Stoffel EM, et al. Racial and ethnic disparities in germline genetic testing of patients with young-onset colorectal cancer. Clin Gastroenterol Hepatol. 2022;20:353&#x2013;361.e3.</Citation></Reference><Reference><Citation>Shia J, Ellis NA, Klimstra DS. The utility of immunohistochemical detection of DNA mismatch repair gene proteins. Virchows Arch. 2004;445:431&#x2013;441.</Citation></Reference><Reference><Citation>Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10:293&#x2013;300.</Citation></Reference><Reference><Citation>Hu C, Hart SN, Polley EC, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319:2401&#x2013;2409.</Citation></Reference><Reference><Citation>Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2:482&#x2013;490.</Citation></Reference><Reference><Citation>Nicolosi P, Ledet E, Yang S, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019;5:523&#x2013;528.</Citation></Reference><Reference><Citation>The National Comprehensive Cancer Network (NCCN) Guidelines, Genetic/Familial High Risk Assessment: Colorectal. Version 1.2021. Accessed June 15, 2021.</Citation></Reference><Reference><Citation>Heald B, Hampel H, Church J, et al.; Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. Fam Cancer. 2020;19:223&#x2013;239.</Citation></Reference><Reference><Citation>Buchanan AH, Datta SK, Skinner CS, et al. Randomized trial of telegenetics vs. in-person cancer genetic counseling: cost, patient satisfaction and attendance. J Genet Couns. 2015;24:961&#x2013;970.</Citation></Reference><Reference><Citation>Ritchie JB, Allen CG, Morrison H, et al. Utilization of health information technology among cancer genetic counselors. Mol Genet Genomic Med. 2020;8:e1315.</Citation></Reference><Reference><Citation>Peterlin B. Telegenetics. Curr Opin Pediatr. 2020;32:739&#x2013;741.</Citation></Reference><Reference><Citation>Mighton C, Shickh S, Uleryk E, Pechlivanoglou P, Bombard Y. Clinical and psychological outcomes of receiving a variant of uncertain significance from multigene panel testing or genomic sequencing: a systematic review and meta-analysis. Genet Med. 2021;23:22&#x2013;33.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>